Small-Cap Firms Were Last Week’s Top Performers. In this article, we are going to take a look at where BioXcel Therapeutics, ...

BioXcel Therapeutics (BTAI) announced that, following the successful raise of $14 million gross proceeds in an equity financing that closed on ...

BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to ...

BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, March 11th. Analysts expect BioXcel Therapeutics to ...

BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares are trading higher Monday following news that the U.S. Food and Drug ...

BioXcel Therapeutics (BTAI) announced that the U.S. Food and Drug Administration has concluded that the inspection of a single site in its ...

BioXcel said the Phase 3 trial is designed to evaluate the safety of BXCL501. The trial's topline-data results, which are expected in the second half of 2025, are intended to support a potential ...

The market expects BioXcel Therapeutics, Inc. (BTAI) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known ...

BioXcel Therapeutics announces 33% enrollment in SERENITY At-Home trial evaluating BXCL501 for agitation treatment, with data expected mid-2025. BioXcel Therapeutics announced that it has achieved ...

NEW HAVEN, Conn., March 03, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial ...